Trials / Completed
CompletedNCT01941082
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, non-randomized, open-label, single- and multiple-ascending-dose study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6867461 in patients with wet age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO6867461 | Single or multiple ascending dose by intravitreal injection |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2013-09-13
- Last updated
- 2016-11-02
Locations
8 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT01941082. Inclusion in this directory is not an endorsement.